SCHEMBL130152

SCHEMBL130152

COC(=O)c1cc(Cl)c(NC(C)=O)cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.72
HPGD P15428 7/20 0.67
ALDH1A1 P00352 7/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
KDM4E B2RXH2 4/20 0.62
LMNA P02545 3/20 0.62
MAPT P10636 3/20 0.62
RAB9A P51151 2/20 0.62
NPY1R P25929 1/20 0.62
NPY2R P49146 1/20 0.62
POLB P06746 1/20 0.62
HSD17B10 Q99714 2/20 0.61
GAA P10253 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
AGER Q15109 1/20 0.58
GLA P06280 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NPC1 O15118 1/20 0.56
PPARG P37231 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14490806 0.91 HTT (0.60) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL14490855 0.89 AGER (0.60) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL7410882 0.88 HTT (0.57) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL133355 0.88 AGER (0.58) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL6962669 0.88 AGER (0.58) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL5925528 0.87 HTT (0.56) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL10827981 0.87 HTT (0.56) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL7367528 0.85 TDP1 (0.59) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL20920574 0.85 AGER (0.62) HTTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL2337975 0.84 HTT (0.67) HTTHPGDALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977827-A Methoxychlor-pram intermediate and preparation method and application thereof 河南优凯制药有限公司 2025-05-13 CN claimed
CN-119977828-A Methoxychlor-pup Process for the preparation of amines 河南优凯制药有限公司 2025-05-13 CN claimed
CN-119912358-A Methoxychlor N-ethyl compound and preparation method and application thereof 河南优凯制药有限公司 2025-05-02 CN claimed
CN-119822987-A Preparation method of 4-acetamido-5-chloro-2-methoxybenzoic acid methyl ester 苏州诚和医药化学有限公司 2025-04-15 CN claimed
CN-117843520-A Methoxychlor-pram intermediate and preparation method and application thereof 常熟泓德生物科技有限公司 2024-04-09 CN claimed
CN-113233992-A Preparation method of 5-chloro-4-acetamido-2-methoxybenzoic acid methyl ester 江苏巨莱生物医药有限公司 2021-08-10 CN claimed
CN-105523952-A Preparation method of methyl 4-acetamido-5-chloro-2-methoxybenzoate JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD 2016-04-27 CN claimed
US-12617780-B2 Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting CTXT PTY LTD (AU) 2026-05-05 US disclosed
CN-119822987-B Preparation method of 4-acetamido-5-chloro-2-methoxybenzoic acid methyl ester 苏州诚和医药化学有限公司 2026-03-24 CN disclosed
CN-119822987-B Preparation method of 4-acetamido-5-chloro-2-methoxybenzoic acid methyl ester 苏州诚和医药化学有限公司 2026-03-24 CN disclosed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 US disclosed
EP-4638460-A1 BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING Aculeus Therapeutics Pty Ltd (AU) 2025-10-29 EP disclosed
CN-119977827-A Methoxychlor-pram intermediate and preparation method and application thereof 河南优凯制药有限公司 2025-05-13 CN disclosed
WO-1989010364-A1 DIBENZOFURANCARBOXAMIDES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-11-02 WO disclosed
EP-0339950-A2 Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1989-11-02 EP disclosed
US-4863921-A Dibenzofurancarboxamides and their pharmaceutical compositions and methods RORER PHARMACEUTICAL CORPORATION (US) 1989-09-05 US disclosed
US-4835172-A Novel benzamides, intermediates and process for the preparation and therapeutic use thereof SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1989-05-30 US disclosed
US-4163789-A Anti-psychotic (cycloalkenylalkylpiperidino) benzamides ANPHAR, S.A. (ES) 1979-08-07 US disclosed
US-4138492-A FOR TREATMENT OF GASTROINTESTINAL DISORDERS ANPHAR, S.A. (ES) 1979-02-06 US disclosed
US-4029673-A N-(1-benzyl pyrrolidinyl 2-alkyl) substituted benzamides and derivatives thereof SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1977-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels BHMT, BHMT2, EHMT2 HTT 1960/4885HPGD 3148/4885ALDH1A1 1296/4885
US-12617780-B2 Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting STING1, CGAS, IRF3 HTT 4402/4885HPGD 2891/4885ALDH1A1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.